Modern aspects of Helicobacter pylori infection

A systematic review of current data on the structure and functions of Helicobacter pylori (Hp), pathogenesis, diagnosis and treatment of Hp-infection is presented. The relevance of the topic of helicobacteriosis is due to the proven connection of this infection with chronic, widespread diseases of the digestive organs among the population. The review used materials from the databases including PubМed, Medline, EMBASE, Scopus, Google Scholar, RSCI. A systematic review based on studies with a high degree of evidence has shown significant progress in the diagnosis and treatment of Hp-infection in recent years in adults and children. Coordination of the scientific search for the regularities of the formation of Hp-associated forms of pathology, continuous improvement of diagnostic technologies and the search for new therapies, periodic well-organized international revisions of standard methods of Hp diagnosis and treatment contribute to the creation of effective methods of Hp eradication, preservation of the optimal composition of the microbiota of the gastrointestinal tract and prevention of antibiotic resistance. Of particular importance for the prevention of complications of Hp-infection are original diagnostic algorithms using specialized endoscopic and molecular technologies before and after Hp eradication with long-term follow-up and the determination of the leading factors correlating with a high risk of stomach cancer. The review indicates the emergence of potentially effective and promising areas for the diagnosis and treatment of Hp-infection, including genetic modification of the Hp genome to ensure its existence as a human symbiont and a significant reduction in its pathogenic properties. At the same time, sequencing of a new generation reveals mutations in Hp genes associated with its pathogenicity and antibiotic resistance, which contributes to the creation of new classes of drugs to increase the effectiveness of Hp eradication with a decrease in the proportion of antibiotics and an increase in pathogenetically significant inhibitors of its pathogenic factors for the prevention of side effects, a significant reduction in the empirical use of several antibiotics and increased compliance to treatment. 

Contributions:
Smirnova G.I., Korsunsky A.A. — concept and design of the study;
Smirnova G.I., Yakovleva N.V. — collection and processing of material, writing text;
Smirnova G.I., Korsunsky A.A. — editing.
All co-authors — approval of the final version of the article, responsibility for the stability of all parts of the article.

Acknowledgment. The study had no sponsorship.

Conflict of interest. The authors declare no conflict of interest.

Received: December 15, 2022
Accepted: January 17, 2023
Published: February 28, 2023

1. Hooi J.K., Lai W.Y., Ng W.K., Suen M.M., Underwood F.E., Tanyingoh D., et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017; 153(2): 420–9. https://doi.org/10.1053/j.gastro.2017.04.022

2. Testerman T.L., Morris J. Beyond the stomach: An updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World J. Gastroenterol. 2014; 20(36): 12781–808. https://doi.org/10.3748/wjg.v20.i36.12781

3. Venneman K., Huybrechts I., Gunter M.J., Vandendaele L., Herrero R., Van Herck K. The epidemiology of Helicobacter pylori infection in Europe and the impact of lifestyle on its natural evolution toward stomach cancer after infection: A systematic review. Helicobacter. 2018; 23(3): e12483. https://doi.org/10.1111/hel.12483

4. Kotilea K., Bontems P., Touati E. Epidemiology, diagnosis and risk factors of Helicobacter pylori infection. Adv. Exp. Med. Biol. 2019; 1149: 17–33. https://doi.org/10.1007/5584_2019_357

5. Sukri A., Hanafiah A., Mohamad Zin N., Kosai N.R. Epidemiology and role of Helicobacter pylori virulence factors in gastric cancer carcinogenesis. APMIS. 2020; 128(2): 150–61. https://doi.org/10.1111/apm.13034

6. Borka Balas R., Meliț L.E., Mărginean C.O. Worldwide prevalence and risk factors of Helicobacter pylori infection in children. Children (Basel). 2022; 9(9): 1359. https://doi.org/10.3390/children9091359

7. Ren S., Cai P., Liu Y., Wang T., Zhang Y., Li Q., et al. Prevalence of Helicobacter pylori infection in China: A systematic review and meta-analysis. J. Gastroenterol. Hepatol. 2022; 37(3): 464–70. https://doi.org/10.1111/jgh.15751

8. Goh K.L., Chan W.K., Shiota S., Yamaoka Y. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter. 2011; 16(Suppl. 01): 1–9. https://doi.org/10.1111/j.1523-5378.2011.00874.x

9. Shah S.C., Iyer P.G., Moss S.F. AGA Clinical practice update on the management of refractory Helicobacter pylori infection: expert review. Gastroenterology. 2021; 160(5): 1831–41. https://doi.org/10.1053/j.gastro.2020.11.059

10. Bel’mer S.V., Kornienko E.A., Volynets G.V., Gurova M.M., Zvyagin A.A., Kamalova A.A., et al. Diagnostics and treatment of Helicobacter pylori infection in children. Eksperimental’naya i klinicheskaya gastroenterologiya. 2021; (9): 119–27. https://doi.org/10.31146/1682-8658-ecg-193-9-119-127 (in Russian)

11. Song Z., Chen Y., Lu H., Zeng Z., Wang W., Liu X., et al. Diagnosis and treatment of Helicobacter pylori infection by physicians in China: A nationwide cross-sectional study. Helicobacter. 2022; 27(3): e12889. https://doi.org/10.1111/hel.12889

12. Lazebnik L.B., Bordin D.S., Dekhnich N.N., Kozlov R.S., Livzan M.A., Lyalyukova E.A., et al. The need to strengthen measures for the diagnosis and treatment of Helicobacter pylori infection in Russia. Eksperimental’naya i klinicheskaya gastroenterologiya. 2021; (3): 83–96. https://doi.org/10.31146/1682-8658-ecg-187-3-83-96 (in Russian)

13. Roberts L.T., Issa P.P., Sinnathamby E.S., Granier M., Mayeux H., Eubanks T.N., et al. Helicobacter pylori: a review of current treatment options in clinical practice. Life (Basel). 2022; 12(12): 2038. https://doi.org/10.3390/life12122038

14. Weyermann M., Adler G., Brenner H., Rothenbacher D. The mother as source of Helicobacter pylori infection. Epidemiology. 2006; 17(3): 332–4. https://doi.org/10.1097/01.ede.0000201257.31155.a0

15. Mladenova I., Durazzo M. Transmission of Helicobacter pylori. Minerva Gastroenterol. Dietol. 2018; 64(3): 251–4. https://doi.org/10.23736/S1121-421X.18.02480-7

16. Violeta Filip P., Cuciureanu D., Sorina Diaconu L., Maria Vladareanu A., Silvia Pop C. MALT lymphoma: epidemiology, clinical diagnosis and treatment. J. Med. Life. 2018; 11(3): 187–93. https://doi.org/10.25122/jml-2018-0035

17. Ahmadi Hedayati M., Khani D., Sheikhesmaeili F., Nouri B. ptk2 and mt2a genes expression in gastritis and gastric cancer patients with Helicobacter pylori infection. Can. J. Gastroenterol. Hepatol. 2022; 2022: 8699408. https://doi.org/10.1155/2022/8699408

18. Santos M.L.C., de Brito B.B., da Silva F.A.F., Sampaio M.M., Marques H.S., Oliveira E., et al. Helicobacter pylori infection: Beyond gastric manifestations. World J. Gastroenterol. 2020; 26(28): 4076–93. https://doi.org/10.3748/wjg.v26.i28.4076

19. Wong F., Rayner-Hartley E., Byrne M.F. Extraintestinal manifestations of Helicobacter pylori: a concise review. World J. Gastroenterol. 2014; 20(34): 11950–61. https://doi.org/10.3748/wjg.v20.i34.11950

20. Lee Y.C., Chiang T.H., Chou C.K., Tu Y.K., Liao W.C., Wu M.S., et al. Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology. 2016; 150(5): 1113–24.e5. https://doi.org/10.1053/j.gastro.2016.01.028

21. Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988; 48(13): 3554–60.

22. Mao X.Y., Xu S.F., Liu Q., Jiang J.X., Zhang H.H., Sang H.M., et al. Anatomical predilection of intestinal metaplasia based on 78,335 endoscopic cases. Saudi J. Gastroenterol. 2016; 22(2): 154–60. https://doi.org/10.4103/1319-3767.178528

23. Mera R.M., Bravo L.E., Camargo M.C., Bravo J.C., Delgado A.G., Romero-Gallo J., et al. Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. Gut. 2018; 67(7): 1239–46. https://doi.org/10.1136/gutjnl-2016-311685

24. Evsyutina Yu.V. Eradication of H. pylori: a modern solution for an old problem. Russkiy Meditsinskiy Zhurnal. 2016; (11): 673–7. (in Russian)

25. Marshall B.J., Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984; 1(8390): 1311–5. https://doi.org/10.1016/S0140-6736(84)91816-6

26. Malfertheiner P., Megraud F., Rokkas T., Gisbert J.P., Liou J.M., Schulz C., et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022; 71(9): 1724–62. https://doi.org/10.1136/gutjnl-2022-327745

27. Jones N.L., Koletzko S., Goodman K., Bontems P., Cadranel S., Casswall T., et al. Joint ESPGHAN/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents. Pediatr. Gastroenterol. Nutr. 2017; 64(6): 1–1003. https://doi.org/10.1097/MPG.0000000000001594

28. Goodwin C.S., Worsley B.W. Microbiology of Helicobacter pylori. Gastroenterol. Clin. North Am. 1993; 22(1): 5–19.

29. Chonwerawong M., Ferrero R.L. Analysis of innate immune responses to Helicobacter pylori. Methods. Mol. Biol. 2021; 2283: 191–214. https://doi.org/10.1007/978-1-0716-1302-3_17

30. De Falco M., Lucariello A., Iaquinto S., Esposito V., Guerra G., De Luca A. Molecular mechanism of Helicobacter pylori pathogenesis. J. Cell Physiol. 2015; 230(8): 1702–7. https://doi.org/10.1002/jcp.24933

31. Jeyamani L., Jayarajan J., Leelakrishnan V., Swaminathan M. CagA and VacA genes of Helicobacter pylori and their clinical relevance. Indian J. Pathol. Microbiol. 2018; 61(1): 66–9. https://doi.org/10.4103/IJPM.IJPM_234_17

32. FitzGerald R., Sinha C., Yadegar A., Smith S.M. Helicobacter pylori virulence factor genotyping. Methods Mol. Biol. 2021; 2283: 93–106. https://doi.org/10.1007/978-1-0716-1302-3_11

33. Hathroubi S., Servetas S.L., Windham I., Merrell D.S., Ottemann K.M. Helicobacter pylori biofilm formation and its potential role in pathogenesis. Microbiol. Mol. Biol. Rev. 2018; 82(2): e00001–18. https://doi.org/10.1128/MMBR.00001-18

34. Engstrand L., Graham D.Y. Microbiome and gastric cancer. Dig. Dis. Sci. 2020; 65(3): 865–73. https://doi.org/10.1007/s10620-020-06101-z

35. Leal Y.A., Flores L.L., Fuentes-Pananá E.M., Cedillo-Rivera R., Torres J. 13C-urea breath test for the diagnosis of Helicobacter pylori infection in children: a systematic review and meta-analysis. Helicobacter. 2011; 16(4): 327–37. https://doi.org/10.1111/j.1523-5378.2011.00863.x

36. Jambi L.K. Systematic review and meta-analysis on the sensitivity and specificity of 13C/14C-urea breath tests in the diagnosis of Helicobacter pylori infection. Diagnostics. 2022; 12: 2428. https://doi.org/10.3390/diagnostics12102428

37. Makristathis A., Hirschl A.M., Mégraud F., Bessède E. Review: Diagnosis of Helicobacter pylori infection. Helicobacter. 2019; 24(1): e12641. https://doi.org/10.1111/hel.12641

38. Godbole G., Mégraud F., Bessède E. Review: Diagnosis of Helicobacter pylori infection. Helicobacter. 2020; 25(Suppl. 1): e12735. https://doi.org/10.1111/hel.12735

39. Sabbagh P., Javanian M., Koppolu V., Vasigala V.R., Ebrahimpour S. Helicobacter pylori infection in children: an overview of diagnostic methods. Eur. J. Clin. Microbiol. Infect. Dis. 2019; 38(6): 1035–45. https://doi.org/10.1007/s10096-019-03502-5

40. Cardos A.I., Maghiar A., Zaha D.C., Pop O., Fritea L., Groza F.M., et al. Evolution of diagnostic methods for Helicobacter pylori infections: From traditional tests to high technology, advanced sensitivity and discrimination tools. Diagnostics (Basel). 2022; 12(2): 508. https://doi.org/10.3390/diagnostics12020508

41. Wei N., Zhong Z., Shi R. A novel method of grading gastric intestinal metaplasia based on the combination of subtype and distribution. Cancer Cell Int. 2021; 21(1): 61. https://doi.org/10.1186/s12935-021-01758-6

42. Saka A., Yagi K., Nimura S. OLGA- and OLGIM-based staging of gastritis using narrow-band imaging magnifying endoscopy. Dig. Endosc. 2015; 27(7): 734–41. https://doi.org/10.1111/den.12483

43. Cheng H.C., Yang Y.J., Yang H.B., Tsai Y.C., Chang W.L., Wu C T., et al. Evolution of the Correa’s cascade steps: A long-term endoscopic surveillance among non-ulcer dyspepsia and gastric ulcer after H. pylori eradication. J. Formos. Med. Assoc. 2022; S0929-6646(22)00430-2. https://doi.org/10.1016/j.jfma.2022.11.008

44. Kharitonova A.Yu., Smirnov I.E., Shavrov A.A., Kalashnikova N.A. Narrow-band imaging endoscopy in the diagnosis of destructive changes in the mucous membrane of the stomach and duodenum in children. Rossiyskiy pediatricheskiy zhurnal. 2012; 15(6): 20–4. (in Russian)

45. Dănilă C., Cardos I.A., Pop-Crisan A., Marc F., Hoza A., Chirla R., et al. Correlations between endoscopic and histopathological assessment of Helicobacter pylori-induced gastric pathology-a cross-sectional retrospective study. Life (Basel). 2022; 12(12): 2096. https://doi.org/10.3390/life12122096

46. Mărginean C.O., Meliț L.E., Săsăran M.O. Traditional and modern diagnostic approaches in diagnosing pediatric Helicobacter pylori infection. Children (Basel). 2022; 9(7): 994. https://doi.org/10.3390/children9070994

47. Nezami B.G., Jani M., Alouani D., Rhoads D.D., Sadri N. Helicobacter pylori mutations detected by next-generation sequencing in formalin-fixed, paraffin-embedded gastric biopsy specimens are associated with treatment failure. J. Clin. Microbiol. 2019; 57(7): e01834-18. https://doi.org/10.1128/JCM.01834-18

48. White J.R., Sami S.S., Reddiar D., Mannath J., Ortiz-Fernández-Sordo J., Beg S., et al. Narrow band imaging and serology in the assessment of premalignant gastric pathology. Scand. J. Gastroenterol. 2018; 53(12): 1611–8. https://doi.org/10.1080/00365521.2018.154245520

49. Pohl D., Keller P.M., Bordier V., Wagner K. Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing. World J. Gastroenterol. 2019; 25(32): 4629–60. https://doi.org/10.3748/wjg.v25.i32.4629

50. Brennan D., O’Morain C., McNamara D., Smith S.M. Molecular detection of antibiotic-resistant Helicobacter pylori. Methods Mol. Biol. 2021; 2283: 29–36. https://doi.org/10.1007/978-1-0716-1302-3_4

51. O’Morain N.R., Dore M.P., O’Connor A.J.P., Gisbert J.P., O’Morain C.A. Treatment of Helicobacter pylori infection in 2018. Helicobacter. 2018; 23(Suppl. 1): e125197. https://doi.org/10.1111/hel.12519

52. Guevara B., Cogdill A.G. Helicobacter pylori: A review of current diagnostic and management strategies. Dig. Dis. Sci. 2020; 65(7): 1917–31. https://doi.org/10.1007/s10620-020-06193-7

53. Georgopoulos S., Papastergiou V. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert. Opin. Pharmacother. 2021; 22(6): 729–41. https://doi.org/10.1080/14656566.2020.1845649

54. Argueta E.A., Ho J.J.C., Elfanagely Y., D’Agata E., Moss S.F. Clinical implication of drug resistance for H. pylori management. Antibiotics (Basel). 2022; 11(12): 1684. https://doi.org/10.3390/antibiotics11121684

55. Li B.Z., Threapleton D.E., Wang J.Y., Xu J.M., Yuan J.Q., Zhang C., et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015; 351: h4052. https://doi.org/10.1136/bmj.h4052

56. Ierardi E., Losurdo G., Fortezza R.F.L., Principi M., Barone M., Leo A.D. Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness. World J. Gastroenterol. 2019; 25(34): 5097–104. https://doi.org/10.3748/wjg.v25.i34.5097

57. Bunchorntavakul C., Buranathawornsom A. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori. J. Gastroenterol. Hepatol. 2021; 36(12): 3308–13. https://doi.org/10.1111/jgh.15700

58. Chey W.D., Mégraud F., Laine L., López L.J., Hunt B.J., Howden C.W. Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology. 2022; 163(3): 608–19. https://doi.org/10.1053/j.gastro.2022.05

59. Kiyotoki S., Nishikawa J., Sakaida I. Efficacy of vonoprazan for Helicobacter pylori eradication. Intern. Med. 2020; 59(2): 153–61. https://doi.org/10.2169/internalmedicine.2521-18

60. Furuta T., Yamade M., Kagami T., Uotani T., Suzuki T., Higuchi T., et al. Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori. Digestion. 2020; 101(6): 743–51. https://doi.org/10.1159/000502287

61. Ouyang Y., Wang M., Xu Y.L., Zhu Y., Lu N.H., Hu Y. Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis. J. Gastroenterol. Hepatol. 2022; 37(9): 1666–72. https://doi.org/10.1111/jgh.15917

62. Yang C., Li S., Huang T., Lin H., Jiang Z., He Y., et al. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials. J. Clin. Pharm. Ther. 2022; 47(7): 897–904. https://doi.org/10.1111/jcpt.13637

63. Suzuki S., Kusano C., Horii T., Ichijima R., Ikehara H. The ideal Helicobacter pylori treatment for the present and the future. Digestion. 2022; 103(1): 62–8. https://doi.org/10.1159/000519413

64. Tanabe H., Yoshino K., Ando K., Nomura Y., Ohta K., Satoh K., et al. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Ann. Clin. Microbiol. Antimicrob. 2018; 17(1): 29. https://doi.org/10.1186/s12941-018-0281-x

65. Hu Y., Zhu Y., Lu N.H. Novel and effective therapeutic regimens for Helicobacter pylori in an era of increasing antibiotic resistance. Front. Cell Infect. Microbiol. 2017; 7: 168. https://doi.org/10.3389/fcimb.2017.00168

66. Zou S.P., Cheng Q., Feng C.Y., Xu C., Sun M.H. Comparative effectiveness of first-line therapies for eradication of antibiotic-resistant Helicobacter pylori strains: A network meta-analysis. World J. Clin. Cases. 2022; 10(35): 12959–70. https://doi.org/10.12998/wjcc.v10.i35.12959

67. Guo Y., Zhang Y., Gerhard M., Gao J.J., Mejias-Luque R., Zhang L., et al. Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer. Gut. 2020; 69(9): 1598–607. https://doi.org/10.1136/gutjnl-2019-319696

68. Sousa C., Ferreira R., Azevedo N.F., Oleastro M., Azeredo J., Figueiredo C., et al. Helicobacter pylori infection: from standard to alternative treatment strategies. Crit. Rev. Microbiol. 2022; 48(3): 376–96. https://doi.org/10.1080/1040841x.2021.1975643

69. Shafaghi A., Pourkazemi A., Khosravani M., Fakhrie Asl S., Amir Maafi A., Atrkar Roshan Z., et al. The effect of probiotic plus prebiotic supplementation on the tolerance and efficacy of Helicobacter pylori eradication quadruple therapy: A randomized prospective double blind controlled trial. Middle East J. Dig. Dis. 2016; 8(3): 179–88. https://doi.org/10.15171/mejdd.2016.30

70. Shi X., Zhang J., Mo L., Shi J., Qin M., Huang X. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis. Medicine (Baltimore). 2019; 98(15): e15180. https://doi.org/10.1097md.0000000000015180

71. Syahniar R., Kharisma D.S., Rayhana R. Helicobacter pylori. Challenge vaccine for humans. In: Desheva Yu., ed. Vaccine Development. Intech Open; 2021. https://doi.org/10.5772/intechopen.101157

72. Malfertheiner P., Selgrad M., Wex T., Romi B., Borgogni E., Spensieri F., et al. Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study. Lancet Gastroenterol. Hepatol. 2018; 3(10): 698–707. https://doi.org/10.1016/s2468-1253(18)30125-0

73. Khan M., Khan S., Ali A., Akbar H., Sayaf A.M., Khan A., et al. Immunoinformatics approaches to explore Helicobacter pylori proteome (Virulence Factors) to design B and T cell multi-epitope subunit vaccine. Sci. Rep. 2019; 9(1): 13321. https://doi.org/10.1038/s41598-019-49354-z

74. Angsantikul P., Thamphiwatana S., Zhang Q., Spiekermann K., Zhuang J., Fang R.H., et al. Coating nanoparticles with gastric epithelial cell membrane for targeted antibiotic delivery against Helicobacter pylori infection. Adv. Ther. (Weinh). 2018; 1(2): 1800016. https://doi.org/10.1002/adtp.201800016

75. Yang S.J., Huang C.H., Yang J.C., Wang C.H., Shieh M.J. Residence time-extended nanoparticles by magnetic field improve the eradication efficiency of Helicobacter pylori. ACS Appl. Mater. Interfaces. 2020; 12(49): 54316–27. https://doi.org/10.1021/acsami.0c13101